{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058629","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.848176+00:00","generated_at":"2026-06-02T02:16:04.601281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024","bullets":["Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.","Cash, equivalents & short-term investments $264.9M as of March 31, 2024, runway into mid-2026.","Topline Phase 3 data for ANX005 in Guillain-Barré Syndrome expected Q2 2024.","Pivotal Phase 3 ARCHER II trial for ANX007 in geographic atrophy to start mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.","Proof-of-concept data for oral ANX1502 in cold agglutinin disease on track for H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058629","json":"https://secwatch.observer/filing/0000950170-24-058629.json","markdown":"https://secwatch.observer/filing/0000950170-24-058629.md","text":"https://secwatch.observer/filing/0000950170-24-058629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/0000950170-24-058629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/annx-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:16:04.601281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90829ef1ab7d7048968abfba394a63ebb4018a42","claim":"Annexon, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/0000950170-24-058629-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}